Enrollment Begins in Africa CDC's Vital MpOx Study
ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo -- Africa CDC is proud to announce the commencement of patient enrollment for the pivotal MOSA clinical trial, focusing on innovative therapeutic options for Mpox. This pan-African randomized platform trial aims to address the growing health threat posed by Mpox, particularly amidst the emergence of Clade Ib cases outside Africa and the continuing reports of Clade I and II cases across the continent.
Mpox Declared a Public Health Emergency
Mpox has been classified as a Public Health Emergency of Continental Security, emphasizing serious health risks faced by vulnerable groups such as women, children, and those living with HIV. As the search for effective treatments continues, there is currently no approved therapeutic available for Mpox in either the United States or Africa. Recent findings from clinical studies have highlighted shortcomings in existing treatments, reinforcing the urgent need for viable therapeutic alternatives.
Leadership in Addressing Health Threats
The launch of the MOSA trial marks a significant step in Africa's commitment to leading global responses to health challenges. This trial will evaluate various antiviral treatments, starting with brincidofovir, an antiviral developed by Emergent BioSolutions. While brincidofovir is currently available in the U.S. under single-use IND for Mpox, thorough research confirming its safety and effectiveness in double-blind studies has yet to be conducted.
Exciting Research Ahead
Patients enrolled in the MpOx Study will receive either brincidofovir or a matching placebo, administered in a liquid formulation once a week for two weeks. An interim analysis of the trial is expected by the end of the first quarter of 2025, giving valuable information on the treatment's efficacy.
African Leadership in Health Initiatives
Dr. Jean Kaseya, Director General of Africa CDC, expressed confidence in the continent's capacity to drive research and development in response to health threats. He emphasized that the MpOx Study exemplifies African leadership in tackling health challenges through innovative research strategies.
Partnerships for Progress
The trial is sponsored by PANTHER, a crucial research partner of Africa CDC, which launched with initial support from the European Union’s Horizon Europe program. Through rigorous ethical and scientific evaluations, the study aims to ensure transparent and efficient decision-making in the face of evolving treatment scenarios.
Importance of Research Preparedness
Marc Lemaître from the European Commission highlighted the vital role this study plays in research preparedness and response, expressing satisfaction at the MOSA study’s operational phase. The insights gleaned from this trial will not only advance treatment options for the ongoing Mpox outbreak but will also prepare us better for future health crises.
Focus on High-Risk Populations
As Africa experiences a persistent rise in Mpox cases, particularly within the DRC, the MOSA trial is committed to gathering essential data for treatment options. By including both children and adults, the study will focus on those most at risk, especially in remote areas where healthcare access may be limited.
Future Implications of the MOSA Trial
Professor Placide Mbala noted that the MOSA trial complements other ongoing studies related to Mpox, including those focused on transmission dynamics, vaccine research, and social aspects of the disease.
Emergent BioSolutions’ Commitment
Dr. Simon Lowry, chief medical officer at Emergent BioSolutions, spoke about the global implications of Mpox as a public health threat, underscoring the collective efforts needed to develop effective treatments and vaccines. He commended the efforts of Africa CDC and PANTHER in advancing the MpOx Study.
About PANTHER and Africa CDC
PANTHER represents the first African-led initiative focused on pandemic preparedness and response, uniting public health teams and researchers to create robust regional research platforms. Meanwhile, the Africa Centres for Disease Control and Prevention serve as a pivotal agency committed to strengthening health systems across Africa, especially in disease surveillance and emergency response.
Learn More
For more information about Africa CDC’s initiatives and the MpOx Study, individuals are encouraged to visit the official websites for ongoing updates.
Frequently Asked Questions
What is the MOSA trial about?
The MOSA trial is an adaptive clinical trial aimed at evaluating therapeutic options for Mpox, initiated by Africa CDC in collaboration with PANTHER.
What treatments are being evaluated in the MOSA trial?
The trial will assess the safety and efficacy of brincidofovir, an antiviral medication, compared to a placebo.
Who is eligible to participate in the trial?
Both children and adults, particularly those at high risk for severe Mpox outcomes, are eligible for enrollment in the trial.
Why is Mpox a public health concern?
Mpox poses significant health risks, especially to vulnerable populations, and there are currently no approved treatments available, prompting the urgent need for research.
How does the MOSA trial contribute to future health responses?
The insights from the MOSA trial will help in advancing treatment options for Mpox and inform preparedness for potential health crises in the future.
